» Articles » PMID: 17909615

The Joint Committee for Traceability in Laboratory Medicine (JCTLM): a Global Approach to Promote the Standardisation of Clinical Laboratory Test Results

Overview
Specialty Biochemistry
Date 2007 Oct 3
PMID 17909615
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical laboratories are moving towards global standardisation to produce equivalent test results across space and time. Standardisation allows use of evidence-based medicine, eliminates the need of method-specific reference intervals, decision levels and cut-offs, and can be achieved by application of metrological principles. For example, in vitro diagnostics (IVD) manufacturers can make kit calibrators traceable to internationally recognised reference materials and reference methods. The first step towards standardisation is to identify appropriate reference materials and methods. This has been undertaken by a new international consortium, the Joint Committee for Traceability in Laboratory Medicine (JCTLM), formed in 2002. It brings together experts representing the clinical laboratory profession, government agencies, and manufacturers, to promote international comparability, reliability, and equivalence of measurement results in clinical laboratories for the purpose of improving healthcare. Through the efforts of the JCTLM, manufacturers are able to assign values to kit calibrators with consistency using appropriate higher order reference materials and methods, and traceability flowcharts, according to ISO Standards to ensure accuracy of test results and to promote assay performance harmonisation. Users of assay kits can assess suitability of calibrators on the basis of acceptable reference materials and/or methods identified by the JCTLM. The JCTLM exemplifies the dynamic nature of clinical laboratory medicine, the inherent spirit of cooperation among professionals in this scientific field, and the international desire to strive for the highest level of clinical laboratory practice for the benefit of patients.

Citing Articles

Biomarkers for Harmful Alcohol Use should be Reliable, Standardised, and Traceable: Only the CDT reference method has been approved by JCTLM and IFCC.

Wielders J, Helander A, Deenmamode J, Weykamp C, Schellenberg F EJIFCC. 2025; 36(1):3-6.

PMID: 40061061 PMC: 11886621.


Human reference microbiome profiles of different body habitats in healthy individuals.

Oh S, Park K Front Cell Infect Microbiol. 2025; 15:1478136.

PMID: 40007609 PMC: 11850547. DOI: 10.3389/fcimb.2025.1478136.


.

Ricos C, Perich C, Bullich S, Ventura M, Piqueras B, Panades M Adv Lab Med. 2023; 4(4):387-395.

PMID: 38106503 PMC: 10724878. DOI: 10.1515/almed-2023-0057.


Compliance to specifications in an external quality assurance program: did new biological variation estimates of the European Federation of Laboratory Medicine (EFLM) affect the quality of laboratory results?.

Ricos C, Perich C, Bullich S, Ventura M, Piqueras B, Panades M Adv Lab Med. 2023; 4(4):379-386.

PMID: 38106488 PMC: 10724879. DOI: 10.1515/almed-2023-0155.


Wearable sensors enable personalized predictions of clinical laboratory measurements.

Dunn J, Kidzinski L, Runge R, Witt D, Hicks J, Schussler-Fiorenza Rose S Nat Med. 2021; 27(6):1105-1112.

PMID: 34031607 PMC: 8293303. DOI: 10.1038/s41591-021-01339-0.


References
1.
Bais R . What information should manufacturers provide on their procedures?. Clin Chem. 2006; 52(8):1624-5. DOI: 10.1373/clinchem.2006.069773. View

2.
Panteghini M, Gerhardt W, Apple F, Dati F, Ravkilde J, Wu A . Quality specifications for cardiac troponin assays. Clin Chem Lab Med. 2001; 39(2):175-9. DOI: 10.1515/cclm.2001.39.2.175. View

3.
Apple F . Standardization of cardiac markers. Scand J Clin Lab Invest Suppl. 2005; 240:107-11. DOI: 10.1080/00365510500236242. View

4.
Christenson R, Duh S, Apple F, Bodor G, Bunk D, Panteghini M . Toward standardization of cardiac troponin I measurements part II: assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays. Clin Chem. 2006; 52(9):1685-92. DOI: 10.1373/clinchem.2006.068437. View

5.
Link R, Shariat S, Nguyen C, Farr A, Weinberg A, Morton R . Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J Urol. 2004; 171(6 Pt 1):2234-8. DOI: 10.1097/01.ju.0000127736.86597.e7. View